HLA-C and neoplasm: As a result, it would be interesting to see if the neoantigens displayed by MHC molecules on tumor cells, especially for those that do not induce the downregulation of MHC I, may change the binding affinity of KIR-MHC and finally modify NK-cell activation (Figure 2).